HDAC3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Vorinostat (SCHEMBL9018)	1.00	14/20
SCHEMBL28250	0.57	14/20
SCHEMBL29476	0.57	14/20
SCHEMBL31064	0.57	14/20
SCHEMBL30259	0.57	14/20
SCHEMBL28328	0.61	13/20
SCHEMBL28329	0.61	13/20
SCHEMBL28330	0.61	13/20
SCHEMBL29695	0.61	13/20
SCHEMBL30199	0.61	13/20
SCHEMBL21138	0.55	12/20
SCHEMBL21139	0.55	12/20
SCHEMBL21140	0.55	12/20
SCHEMBL30622	0.55	12/20
SCHEMBL34229	0.51	12/20
Trichostatin (SCHEMBL19886)	1.00	10/20
SCHEMBL19539	0.48	10/20
SCHEMBL29911	0.45	10/20
SCHEMBL29912	0.45	10/20
SCHEMBL29913	0.45	10/20

Clinical trials — most relevant to HDAC3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Chidamide Combined With Toripalimab in Sarcoma	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma	PHASE2	COMPLETED
Voronistat in Pediatric Patients With Drug Resistant Epilepsy	PHASE2	UNKNOWN
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer	PHASE2	UNKNOWN
Vorinostat in Children	PHASE1/PHASE2	COMPLETED
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma	PHASE2	COMPLETED
Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia	PHASE2	RECRUITING
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors	PHASE1	COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	PHASE1	COMPLETED
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia	PHASE1	COMPLETED
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes	PHASE1	COMPLETED
Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors	PHASE1	COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers	PHASE1	COMPLETED
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma	PHASE1	COMPLETED
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome	nan	UNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING
Imaging Histone Deacetylase in the Heart	nan	RECRUITING
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Correlation Between Trachebroncho Malacia/Hyperdynamic Airway Collapse And Obstructive Sleep Apnea	nan	COMPLETED
Chi-GVM Regimen for the Treatment of R/R PTCL	nan	UNKNOWN
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a HDAC3 binder may also engage these)

Protein	Name	Similarity
O88895	—	1.000	O88895 →
Q6P6W3	—	1.000	Q6P6W3 →
Q803C3	—	1.000	Q803C3 →
Q5RB76	—	1.000	Q5RB76 →
Q4SFA0	—	1.000	Q4SFA0 →
Q6IRL9	—	1.000	Q6IRL9 →
Q8H0W2	—	0.997	Q8H0W2 →
O13298	—	0.997	O13298 →
P56520	—	0.997	P56520 →
Q28DV3	—	0.996	Q28DV3 →
Q55BW2	—	0.996	Q55BW2 →
O59702	—	0.992	O59702 →
Q32PJ8	—	0.990	Q32PJ8 →
P56517	—	0.990	P56517 →
Q5RAG0	—	0.990	Q5RAG0 →
O09106	—	0.990	O09106 →
Q9FML2	—	0.989	Q9FML2 →
P32561	—	0.989	P32561 →
O17695	—	0.989	O17695 →
Q91695	—	0.988	Q91695 →
Q9FH09	—	0.988	Q9FH09 →
P56519	—	0.988	P56519 →
P53096	—	0.987	P53096 →
Q7Y0Y8	—	0.987	Q7Y0Y8 →
P70288	—	0.987	P70288 →
Q7Y0Y6	—	0.987	Q7Y0Y6 →
Q4QQW4	—	0.987	Q4QQW4 →
Q55FN5	—	0.986	Q55FN5 →
Q94517	—	0.986	Q94517 →
HDAC2	Histone deacetylase 2	0.985	landscape →